Literature DB >> 1133087

The development of nephrocalcinosis in the rat following injections of neutral sodium phosphate.

P Haase.   

Abstract

The development of nephrocalcinosis in the rat following intraperitoneal injections of various concentrations of neutral sodium phosphate (pH 7-4) was studied using histology, histochemistry, electron microscopy and quantitative techniques. Daily injections of 0-5 M phosphate consistently produced nephrocalcinosis after 6 days or more. Calcium deposits were at first confined to the basement membranes of proximal tubules; but a longer course of injections, up to 10 days, resulted in additional basement membrane calcification in the outer cortes, and outer medulla, together with intra-luminal casts, often calcified, in the outer medulla and papilla. Calcification was not found in other organs such as liver, lung, heart or aorta. Results from quantitative estimations of total kidney calcium and phosphorus suggested that it was the calcium content which was important to the initiation of nephrocalcinosis. Ultrastructural changes, suggestive of degeneration or alteration in function, were found in mitochondria of proximal tubules in experimental animals before the onset of histologically evident nephrocalcinosis. Later changes, especially to the basal part of proximal tubular cells and their basal laminae, were thought to be consequent upon the mitochondrial changes. It is suggested that the initial renal damage was caused both directly, by a toxic effect of the phosphate load on the kidney and, indirectly, by stimulation of the parathyroid glands as a result of the hypocalcaemia and hyperphosphataemia which followed an injection of phosphate. Daily doses of 1 M phosphate for 3 days produced a type of nephrocalcinosis which was more typical of that reported by previous investigators, who used high doses of phosphate. Twice daily injections of 0-25 M phosphate for 6 days did not induce nephrocalcinosis, whereas 0-375 M phosphate given twice daily for 6 days produced only minimal calcium deposits compared with animals given 0-5 M phosphate once daily for the same period. This may have important clinical implications, since phosphate has been used to control hypercalcaemia of various etiologies.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1133087      PMCID: PMC1231612     

Source DB:  PubMed          Journal:  J Anat        ISSN: 0021-8782            Impact factor:   2.610


  23 in total

1.  Ground substance and calcification; the influence of dye binding on experimental nephrocalcinosis.

Authors:  R BAKER; G REAVEN; J SAWYER
Journal:  J Urol       Date:  1954-05       Impact factor: 7.450

2.  The inhibition of respiration and phosphorylation in kidney mitochondria by parathyroid hormone administered in vivo.

Authors:  D V Cohn; A F Smaich; R Levy
Journal:  J Biol Chem       Date:  1966-02-25       Impact factor: 5.157

3.  Molecular and ultrastructural studies of non-crystalline calcium phosphates.

Authors:  M U Nylen; E D Eanes; J D Termine
Journal:  Calcif Tissue Res       Date:  1972

4.  The effect of parathyroid hormone in vivo on the accumulation of calcium and phosphate by kidney and on kidney mitochondrial function.

Authors:  D V Cohn; R Bawdon; G Eller
Journal:  J Biol Chem       Date:  1967-03-25       Impact factor: 5.157

5.  Prevention of phosphate-induced nephrocalcinosis by parathyroidectomy.

Authors:  I Clark; F Rivera-Cordero
Journal:  Proc Soc Exp Biol Med       Date:  1972-03

6.  [Acute tubular nephropathy and late radiologic vacular calcifications following treatment of a hypercalcemia with intravenous administration of phosphates].

Authors:  C Bernheim; T Vischer
Journal:  Schweiz Med Wochenschr       Date:  1968-04-27

7.  Massive extraskeletal calcification during phosphate treatment of hypercalcemia.

Authors:  R W Carey; G W Schmitt; H H Kopald; P A Kantrowitz
Journal:  Arch Intern Med       Date:  1968-08

8.  Kinetic analyses of calcium movements in cell cultures. IV. Effects of phosphate and parathyroid hormone in kidney cells.

Authors:  A B Borle
Journal:  Endocrinology       Date:  1970-06       Impact factor: 4.736

9.  Caution in the use of phosphates in the treatment of severe hypercalcemia.

Authors:  R I Breuer; J LeBauer
Journal:  J Clin Endocrinol Metab       Date:  1967-05       Impact factor: 5.958

10.  Precipitous fall in serum calcium, hypotension, and acute renal failure after intravenous phosphate therapy for hypercalcemia. Report of two cases.

Authors:  S Shackney; J Hasson
Journal:  Ann Intern Med       Date:  1967-05       Impact factor: 25.391

View more
  6 in total

1.  Osteopontin protects against high phosphate-induced nephrocalcinosis and vascular calcification.

Authors:  Neil J Paloian; Elizabeth M Leaf; Cecilia M Giachelli
Journal:  Kidney Int       Date:  2016-03-09       Impact factor: 10.612

2.  Parathyroid stimulation in phosphate-induced nephrocalcinosis.

Authors:  P Haase
Journal:  J Anat       Date:  1978-02       Impact factor: 2.610

3.  Dietary induction of renal mineralization in dogs.

Authors:  R E Schmidt; G B Hubbard; J L Booker; C A Gleiser
Journal:  Can J Comp Med       Date:  1980-10

4.  Medullary nephrocalcinosis in nephropathic cystinosis.

Authors:  D S Theodoropoulos; T H Shawker; C Heinrichs; W A Gahl
Journal:  Pediatr Nephrol       Date:  1995-08       Impact factor: 3.714

5.  Phosphate and the development of nephrocalcinosis in rats fed diets containing alpha protein.

Authors:  R K Zalups; P Haase; D J Philbrick
Journal:  Am J Pathol       Date:  1983-10       Impact factor: 4.307

6.  Evaluation of four animal models of intrarenal calcium deposition and assessment of the influence of dietary supplementation with essential fatty acids on calcification.

Authors:  N A Burgess; T M Reynolds; N Williams; A Pathy; S Smith
Journal:  Urol Res       Date:  1995
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.